Mechanism of Action: Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors

Drugs with Mechanism of Action: Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-001	Feb 1, 2023		DISCN	Yes	No			Y
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-003	Feb 1, 2023		DISCN	Yes	No			Y	Y
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-002	Feb 1, 2023		DISCN	Yes	No				Y
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-004	Feb 1, 2023		DISCN	Yes	No

Last updated: June 25, 2026

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHI): Market Dynamics and Patent Landscape for HIF-PHI Drugs

Executive summary: HIF-prolyl hydroxylase inhibitors (HIF-PHIs) have shifted anemia-of-CKD and related hypoxia-driven indications toward oral, small-molecule therapy, but the patent landscape remains front-loaded in early-life compound and formulation protection plus late-stage life-cycle rights (polymorphs, salt forms, solid-state forms, and extended dosing regimens). Competitive entry risk is shaped less by broad class exclusivity and more by each drug’s Orange Book and patent estate granularity, including method-of-use patents tied to anemia endpoints and label-specific dosing. The practical market dynamic is a race between (1) incremental patent-protected line extensions and (2) generic or biosimilar-style “small-molecule” entry pressure through ANDA Paragraph IV filing, where litigation timelines and settlement terms determine entry timing and pricing.

Which HIF prolyl hydroxylase inhibitors dominate the market and how do they compete?

Featured snippet answer: The leading marketed HIF-PHIs for anemia include roxadustat (Roxadustat/FN), daprodustat (Duvroq), and vadadustat (Jesduvroq). Competition centers on oral dosing convenience, dialysis versus non-dialysis label coverage, and payer protocols that compare total anemia management cost, including ESA avoidance and transfusion rates.

What are the main commercially relevant HIF-PHI drugs and their labeled scopes?

Commercial relevance is tied to (a) FDA-approved anemia indications, (b) dialysis patient subset coverage, and (c) dosing frequency that affects adherence and clinic workflows.

Key marketed HIF-PHI products (FDA context)

• Roxadustat (Japan launch history; US approvals are limited by regulatory and competitive positioning in this framing)
• Daprodustat (brand Duvroq)
• Vadadustat (brand Jesduvroq)

How do pricing and payer dynamics affect adoption?

Payer dynamics typically hinge on:

• interchangeability with ESAs and iron strategies
• dialysis-center protocol adoption
• anemia management performance by subgroup (dialysis vs non-dialysis; baseline iron status)
• reimbursement guardrails tied to hemoglobin targets and monitoring requirements

Which competitive levers drive utilization beyond clinical efficacy?

• Formulary access: step therapy against ESAs and iron-only pathways.
• Switching economics: center incentives for reducing injection administration and related nursing time.
• Safety monitoring workflow: iron studies and hemoglobin monitoring schedules that align with standard CKD anemia care.

What patents protect HIF-PHI drugs and how are they organized across the estate?

Featured snippet answer: HIF-PHI estates typically split into early-life IP (composition of matter for the active) and late-life IP (polymorphs, salts, crystal forms, amorphous forms, solid-state manufacturing methods, and formulation compositions), plus method-of-use patents that map to labeled anemia dosing and hemoglobin response targets.

How many patent families usually cover each HIF-PHI?

A class pattern is visible even when patent counts differ by jurisdiction:

• Core composition families: multiple continuations or related filings around the heterocycle core, substituent permutations, and stereochemistry where relevant.
• Solid-state/physicochemical families: polymorph, salt, hydrate, and crystallinity claims that can extend exclusivity even after “active” compound claims age out.
• Formulation families: tablets/capsules, coatings, excipient systems, and manufacturing processes.
• Method-of-use families: dosing regimens and anemia treatment endpoints tied to “therapeutic effect” claims.

Typical claim clusters in HIF-PHI patent estates

1. Composition of matter
   • chemical structure claims to the HIF-prolyl hydroxylase inhibitor
   • protected salts and solvates when claimed
2. Solid-state forms
   • polymorph/crystal form identifiers
   • preparation routes that yield specific solid states
3. Formulations
   • tablet or capsule compositions with defined excipients
   • dissolution/particle size constraints
4. Methods of treatment
   • treating anemia of CKD using an oral HIF-PHI
   • dosing frequency and titration concepts tied to hemoglobin targets
   • use with iron management protocols (sometimes as combinatorial claims)

Which legal and regulatory mechanisms most influence exclusivity outcomes?

• FDA Orange Book listings for approved small molecules
• Patent term adjustments and extensions (where applicable)
• Patent litigation under ANDA Paragraph IV for generics
• Settlement agreements that can control “at-risk” launch timing

When does HIF-PHI patent protection expire and what drives exclusivity loss dates?

Featured snippet answer: Exclusivity loss is driven by the earliest priority date plus patent term calculations, then extended by patent term adjustments and term extensions, with parallel wind-down timelines governed by the last listed patent(s) in the Orange Book and any court-imposed injunction durations.

What are the key dates that define the exclusivity timeline?

• Earliest priority date (often from the earliest compound or intermediate filing)
• First US filing date and grant history
• Patent term extension (if granted) tied to regulatory review history
• Orange Book “listed” patent expiration for each relevant claim
• Litigation and settlement timelines, which determine when generics can launch notwithstanding “wall” dates

How do multiple patents change the “real” launch window?

Even when the core composition patent expires, remaining:

• formulation patents (specific tablet/capsule solid-state or composition)
• method-of-use patents tied to dosing and target hemoglobin ranges can delay generic substitutes that do not “design around” claim elements.

What is the Orange Book status of daprodustat and vadadustat?

Featured snippet answer: Orange Book status is the operational exclusivity map for generic entry. For HIF-PHIs, it typically includes both core compound and downstream patents. The most restrictive listed patents often end up being formulation or method-of-use patents with later expirations.

What Orange Book patent types usually appear for HIF-PHIs?

• Drug substance patents (active compound and salts)
• Drug product/formulation patents (solid-state forms and tablets)
• Method-of-use patents tied to anemia treatment regimens

How does Orange Book listing affect ANDA Paragraph IV strategy?

Paragraph IV filers typically target the latest-expiring patents or assert non-infringement/invalidity for the specific listed claims tied to:

• the relevant solid state
• the specific formulation composition
• method-of-use dosing and titration

Which formulations are protected by HIF-PHI patents and what design-around options exist?

Featured snippet answer: Formulation protection often targets particle size, excipient composition, coating systems, and solid-state properties (polymorph/crystal form, specific hydrates/solvates, and manufacturing conditions). Generic design-around must avoid infringing claim elements tied to those properties.

What formulation elements are commonly claimed in HIF-PHI product patents?

• tablet core excipient ranges and relative amounts
• coating compositions and dissolution modifiers
• solid-state identity constraints (polymorph/hydrate naming or characterization parameters)
• preparation method steps that yield a specified solid form

What manufacturing/IP barriers slow generic development?

• sourcing or generating the claimed solid state at scale
• demonstrating equivalence while avoiding infringement
• aligning bioequivalence studies with a formulation that does not replicate a protected structure

What patent litigation affects HIF-PHI drugs and how do settlements change generic entry?

Featured snippet answer: HIF-PHI litigation risk is concentrated around ANDA Paragraph IV challenges to Orange Book-listed patents. Settlements usually convert “at-risk” timelines into agreed-for-delayed launch dates, often tied to the latest expiring patents or earlier carve-outs.

How do Paragraph IV cases typically unfold in this drug class?

• filer selects a set of patents to challenge
• litigation triggers automatic 30-month stay if not settled earlier
• courts adjudicate infringement/invalidity or settlement resolves timing
• design-around products still require compliance with the non-challenged patents and regulatory acceptance

What settlement terms matter to market forecasting?

• date of “authorized” launch
• whether label and dosing schedules must match
• scope of injunction (sometimes limited to specific dosages/strengths)
• cross-licensing of technology (rare but possible where solid-state or formulation know-how is central)

What generic entry risks exist for HIF-PHI drugs?

Featured snippet answer: Generic entry risk is highest where (a) key formulation or method-of-use patents expire earlier than core compound patents, (b) Paragraph IV challenges successfully invalidate or narrow claims, or (c) settlements carve out specific dosages/strengths for earlier launch.

What factors determine whether generics can launch at the earliest date?

• whether the generic can obtain non-infringing solid-state form and formulation
• whether method-of-use claims are still enforceable against the proposed label
• whether the generic’s ANDA certification includes carve-outs that satisfy statutory requirements
• whether litigation stays are lifted by settlement

How does dosing and strength granularity create pocketed exclusivity?

HIF-PHIs often come in multiple strengths and dialysis/non-dialysis workflows. Even if one patent is designed around, other patents covering particular strengths can delay full substitution.

How do HIF-PHI patents compare with ESA/IP in CKD anemia competition?

Featured snippet answer: ESA/protein biologic estates are structurally different (biologic exclusivity frameworks, biosimilar pathways, and distinct patent/biologics exclusivity rules). HIF-PHIs are small molecules, so the competitive boundary is usually framed as ANDA Paragraph IV patent battles rather than BPCIA biosimilar litigation.

What competitive switching patterns are typical?

• switching from ESAs to HIF-PHIs based on convenience and reduced injection schedules
• adjustment of iron monitoring protocols as the oral therapy changes anemia management dynamics

What FDA pathway milestones matter for patent and entry timing?

Featured snippet answer: For small-molecule generics, ANDA approval timing depends on regulatory pathway completion, but patent triggers govern launch. For innovators, the pathway affects when patents appear in the Orange Book and which exclusivity windows apply.

Which FDA actions feed into exclusivity and labeling boundaries?

• initial approval and subsequent label expansions (dialysis vs non-dialysis; dosing constraints)
• supplemental approvals that add strengths or change titration language
• naming and strength mapping that affects whether generics can partially launch under existing certifications

Key Takeaways

• HIF-PHI market dynamics are driven by oral administration convenience and CKD anemia workflow integration, with payer access and center protocols as major adoption levers.
• The patent landscape is structured around four recurring claim clusters: composition of matter, solid-state form, formulation composition, and method-of-use dosing/regimen claims.
• Exclusivity loss and generic entry timing are governed by the last enforceable Orange Book-listed patents, not by the earliest active compound patent alone.
• Formulation and solid-state patents create the most durable design-around challenges, while method-of-use patents map directly to label-specific dosing and hemoglobin target claims.
• ANDA Paragraph IV litigation and settlements typically determine the practical launch window more than statutory expiry alone.

FAQs

1. Which HIF-PHI patents usually survive the longest and block generic launch the most effectively?
2. How do solid-state polymorph or hydrate patents affect the feasibility of an ANDA for HIF-PHIs?
3. What is the difference between Orange Book “drug product” patents and “drug substance” patents for HIF-PHI entry risk?
4. How do settlements in Paragraph IV HIF-PHI cases typically structure launch dates by strength or dosing regimen?
5. What label or dosing changes can trigger new method-of-use patent coverage for HIF-PHIs?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
2. U.S. Food and Drug Administration. ANDA regulations under section 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355(j)).
3. U.S. Code. Hatch-Waxman Act provisions relating to patent certification and 30-month stay (21 U.S.C. § 355(j)(5)).